Betterlife Pharma Inc Stock Price, News & Analysis

BetterLife Pharma has issued a statement addressing the BCSC's May 21, 2025 news release regarding CEO Dr. Ahmad Doroudian's share position ownership. The company had previously amended its Management Information Circulars (MIC) on July 16, 2024, to correct disclosures of beneficial ownership. The corrections show various adjustments in reported share ownership, most notably from 9,161,929 (9.455%) to 21,330,518 (22.01%) for February 2019. Since early 2023, Dr. Doroudian has increased his ownership from 5.8M to 16M shares through a direct investment of $675,000 and salary settlements in shares. Despite expressing disappointment about the BCSC penalty, Dr. Doroudian remains optimistic about BetterLife and its lead asset BETR-001.

BetterLife Pharma has presented promising preclinical data for BETR-001, its proprietary non-hallucinogenic compound for treating psychiatric disorders. The drug shows a breakthrough mechanism by selectively activating the 5HT2A receptor to 60%, staying below the 70% hallucination threshold, unlike LSD which activates it to 90%. Key advantages include: no 5HT2B receptor activation (improving cardiac safety), no tolerance development allowing daily dosing, and potential for at-home administration as a non-controlled substance. The company has secured USPTO patent protection and completed most IND-enabling studies, with human trials projected to begin in H1 2026. BETR-001's unique properties position it as a potential new paradigm for treating depression, anxiety, and PTSD.

BetterLife Pharma (OTCQB: BETRF), a biotech company developing BETR-001 for psychiatric and neurological disorders, has announced significant debt settlements through share issuance. The company issued 14,999,303 common shares to settle accounts payable and amounts due totaling $1,499,930. Of this, company officers and directors settled $1.03 million in debt for 10,308,039 shares. Additionally, BetterLife raised $25,000 through the exercise of 250,000 share purchase warrants. The newly issued shares will be subject to a four-month hold period under Canadian securities laws.

BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has appointed André Beaudry as Corporate Advisor. Beaudry brings over 30 years of experience in fundraising, government relations, and international program management, having secured over $140M for various initiatives including mental health across multiple countries.

As Founder of Velocity Collaboration , Beaudry is also a shareholder of BetterLife and will focus on advancing BETR-001, the company's patented non-hallucinogenic compound. The drug has completed most FDA required IND-enabling studies and aims to treat anxiety, depression, PTSD, addiction, chronic migraine, and cluster headaches by renewing neural circuits affected by chronic stress or trauma.

BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha brings 25 years of experience in investment banking, business development, and asset management, along with expertise in public company governance and compliance. He holds a Doctorate of Dental Surgery from the University of Western Ontario and a Bachelor of Pharmaceutical Science from UBC.

As the largest shareholder of BetterLife, Dr. Sangha expressed confidence in BETR-001, describing it as the best asset in its class for treating depression, anxiety, PTSD, and addiction. The company is focusing on developing non-hallucinogenic compounds for psychiatric and neurological disorders, with plans to advance BETR-001 to human clinical trials in the near future.

BetterLife Pharma (CSE: BETR / OTCQB: BETRF / FRA: NPAU), a biotech company developing BETR-001 (a non-hallucinogenic LSD derivative), has announced debt conversions. The company has issued 642,329 common shares and an equal number of share purchase warrants following the conversion of convertible debentures and accrued interest totaling $64,232.88.

The share purchase warrants can be exercised on a one-for-one basis at $0.10 per warrant, with expiration dates set for September 27, 2026, and October 29, 2026.

BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), an emerging biotech company, announced that the USPTO has granted the BETR-001 composition of matter patent (US2023/0219955), expiring in 2042. BETR-001 is a non-hallucinogenic derivative of LSD. This new patent adds to BetterLife's existing intellectual property, which includes patents for the synthesis of 2-bromo-LSD (US9,868,732B2 and US10,377,752B2) issued in 2018 and 2019.

Dr. Ahmad Doroudian, CEO of BetterLife, stated that this patent is a significant milestone, ensuring the commercial potential of BETR-001, the R:R stereoisomer of 2-bromo-LSD. BetterLife is the first to demonstrate that the R:R stereoisomer is active at the neuroreceptors involved in treating various mental health disorders.

The company is actively pursuing additional claims such as method-of-use and has filed other patent applications covering BETR-001 and other forms of 2-bromo-LSD. BetterLife is confident in its strong intellectual property position and the commercial viability of BETR-001.

BetterLife Pharma (CSE: BETR / OTCQB: BETRF) announced a favorable outcome in legal claims filed against the company and its subsidiary, MedMelior. The case, initiated in early 2021 by a former MedMelior director seeking US$12.5 million in damages, has concluded with no obligations for BetterLife.

The resolution came through a series of New York state and federal court dismissals on grounds of forum non conveniens. The former director's subsequent federal appeal attempt lapsed in early November after unsuccessful settlement attempts, effectively ending the legal proceedings without any payments or penalties against the company.

BetterLife Pharma has announced favorable cardiac safety data for its drug candidate BETR-001, a non-hallucinogenic derivative of LSD. The company completed GLP in vitro studies showing minimal impact on the hERG channel, important for cardiac functioning. The results align with previous in vivo cardiac safety telemetry studies and complement findings on BETR-001's activity at the 5HT-2B receptor, where it acts as an antagonist rather than an agonist. This is significant as agonism at 5HT-2B receptor is associated with cardiac valvulopathy. These positive results bring the company closer to completing IND-enabling studies and initiating clinical trials.